A Phase 1a/1b Study of COM701 as Monotherapy and in Combination with an Anti-PD1 Antibody in Subjects with Advanced Solid Tumors
Study of COM701 Alone and in Combination with Nivolumain in Patients with Advanced Solid Tumors (Breast Cancer/Ovarian Cancer/Lung Cancer)
Sponsor: Compugen Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR9998
U.S. Govt. ID: NCT03667716
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The main purposes of this research study are: to find a safe and tolerated dose of the study drug COM701 alone and in combination with nivolumab; and to measure the amount of COM701 that is in the blood at different times after it is given. This study is for people with advanced cancer (solid tumor) that no longer responds to standard approved therapies.
Investigator
Benjamin Izar, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have breast, ovarian, or lung cancer? Yes No
Do you have a tumor that continues to grow for which you have already received standard therapy? Yes No
Are you willing to possibly undergo additional biopsies? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162